EUVIMEDEUVIMED entdecken
Fallbericht

A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment

Satoshi Hirano, Hidekazu Takahashi, Sukeyuki Nakamura, Kousei Matsuda, Rintaro Ishikawa, Kei Tamura, Kohei Shikano, Tetsuo Fujita, Hiroyuki Amano, Makoto Nakamura

Chinese Clinical Oncology · 2024

DOI: 10.21037/cco-23-153 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Chinese Clinical Oncology, 2024. Verfasst von Satoshi Hirano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Funabashi Municipal Medical Center, Funabashi, Chiba, Japan. Hauptthemen laut MEDLINE: Nivolumab, Tuberculosis, Pulmonary, Adenocarcinoma of Lung, Ipilimumab. Die Arbeit wurde bisher 7-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become key agents in the treatment of non-small cell lung cancer worldwide. However, immune-related adverse events (irAEs) must be addressed to maximize the efficacy of ICIs. Mycobacterium tuberculosis (Mtb) infection is considered as a type of irAE associated with ICIs, but the underlying mechanism is not completely understood. Here, we present a case of pulmonary tuberculosis (TB) that developed during administration of nivolumab and ipilimumab for pulmonary adenocarcinoma that recurred just 2 months after completion of anti-TB treatment. CASE DESCRIPTION: A 67-year-old man with lung adenocarcinoma was referred to our hospital for chemotherapy. He was a former smoker and had been diagnosed with stage IVA (cT4N1M1a) lung adenocarcinoma. Interferon-gamma release assay (IGRA) yielded positive results at the start of treatment. One month after initiating treatment with nivolumab and ipilimumab, he presented with productive cough and Mtb complex was cultured from sputum samples. Two months after completing anti-TB treatment, recurrence of TB was observed. The series of strains were found to be identical. CONCLUSIONS: This represents the first report of pulmonary TB that developed during nivolumab and ipilimumab treatment, and recurred 2 months after completing anti-TB treatment. Physicians should be mindful of the potential for TB recurrence following the use of ICIs, particularly in patients showing positive results from IGRA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabTuberculosis, PulmonaryAdenocarcinoma of LungIpilimumabHumansMaleAgedLung NeoplasmsAntitubercular AgentsAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

Case reportipilimumablung cancernivolumabtuberculosis (TB)

Substanzen

NivolumabIpilimumabAntitubercular AgentsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Medical Oncology, Funabashi Municipal Medical Center, Funabashi, Chiba, Japan.
  • Department of Respiratory Medicine, Funabashi Municipal Medical Center, Funabashi, Chiba, Japan.

Zitieren

APA

Hirano, S., Takahashi, H., Nakamura, S., Matsuda, K., Ishikawa, R., Tamura, K., Shikano, K., Fujita, T., Amano, H., & Nakamura, M. (2024). A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment. Chinese Clinical Oncology. https://doi.org/10.21037/cco-23-153

Vancouver

Hirano S, Takahashi H, Nakamura S, Matsuda K, Ishikawa R, Tamura K, et al. A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment. Chinese Clinical Oncology. 2024. doi:10.21037/cco-23-153

BibTeX
@article{Hirano2024,
  author = {Hirano, Satoshi and Takahashi, Hidekazu and Nakamura, Sukeyuki and Matsuda, Kousei and Ishikawa, Rintaro and Tamura, Kei and Shikano, Kohei and Fujita, Tetsuo and Amano, Hiroyuki and Nakamura, Makoto},
  title = {A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment},
  journal = {Chinese Clinical Oncology},
  year = {2024},
  doi = {10.21037/cco-23-153}
}
Kostenlos starten →